Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is opening the Ecolab Healthcare Advanced Design Center in Eagan, Minn.
Biotech Cleanroom Industry Articles
Picocyl Expands Product Line and Production Capacity as Demand for Pico-Cylinders Soars
As new and novel drug therapies are developed to address areas where conventional medicines are limited, drug delivery innovators, designers and manufacturers have turned to Picocyl for its unique, patented power solutions for drug and implant delivery systems.
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
Cardiology Laboratory Serves Bayer Strategic Alliance
Bayer Strategic Partnership formed. Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure.
Quantum Computing One Step Closer
An international team has developed a ground-breaking single-electron “pump”. The electron pump device developed by the researchers can produce one billion electrons per second and uses quantum mechanics to control them one-by-one. And it’s so precise they have been able to use this device to measure the limitations of current electronics equipment.
Robotic Hand with Brainy Skin Enables Sense of Touch
University of Glasgow’s Professor Ravinder Dahiya has plans to develop ultra-flexible, synthetic Brainy Skin that ‘thinks for itself’. The super-flexible, hypersensitive skin may one day be used to make more responsive prosthetics for amputees, or to build a robotic hand with a sense of touch.
Machine Learning Sifts & Searches Complex Scientific Data
A team of researchers from the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) and UC Berkeley are developing innovative machine learning tools to pull contextual information from scientific datasets and automatically generate metadata tags for each file. Scientists can then search these files via a web-based search engine for scientific data, called Science Search, that the Berkeley team is building.
Why Bacteria Spores Survive in Space – UH Biologists Discover Clues
Bacterial spores from Earth still manage to find their way into outer space aboard spacecraft. Fox and his team are examining how and why some spores elude decontamination. Their research is published in “BMC Microbiology.”
MOF Nanoparticles Used to Deliver Killer Protein to Cancer
In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles.
CO2 Electrochemical Reduction Unveils Renewable Energy Opportunities
Researchers uncovered a heterogeneous catalysis strategy that deliberately targets post-C-C coupling reaction intermediates during CO2 electrochemical reduction reaction. It opens avenues to the design of efficient catalysts that selectively produce higher-carbon liquid alcohols.
Vertex Pharmaceuticals Acquires CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.
Cystic Fibrosis Therapy Improved by Lipid-Based Nanoparticles
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients. Cystic fibrosis is a progressive genetic disorder that results in persistent lung infection and afflicts 30,000 people in the U.S., with about 1,000 new cases diagnosed every year.